Adverse Event Management

Brain Cancer

Breast Cancer

Childhood/AYA Cancer

Disparities in Cancer Care

Drug Safety

Gastrointestinal Cancer

Genetics

Genitourinary Cancer

Gynecologic Cancers

Head and Neck Cancers

Hematology

Immuno-Oncology

Lung Cancer

Myeloproliferative Neoplasms

Nurse Navigation

Prevention

Radiation Oncology

Sarcomas

Skin Cancer/Melanoma

Supportive Care

Survivorship

Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease. 

Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups 

Quizartinib plus standard intensive induction and consolidation therapy was associated with longer survival rates in patients with FLT3-ITD–positive acute myeloid leukemia. 

Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML 

The confirmed objective response rate with repotrectinib was 79% among tyrosine kinase inhibitor (TKI)-naïve patients and 38% among TKI-pretreated patients. 

Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC 

The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone. 

Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo

News

FDA News

Latest News

Oncology Drug Crash Course

Media

Insights

Medical World News

Peer Exchange

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Contributors

Webinars

Subscribe

Partners

Articles

The pathological complete response among patients who received durvalumab plus chemotherapy was 17.2% vs 4.3% in the placebo plus chemotherapy arm. 

Perioperative Durvalumab Plus Chemo Boosts pCR, EFS in Resectable NSCLC

Data suggest that frontline treatment brentuximab vedotin elicits superior outcomes in patients with Hodgkin Lymphoma, regardless of PET2 results. 

Interim PET2 Scans May Be Redundant in Frontline Brentuximab Vedotin Regimens Treatments for Hodgkin Lymphoma

The FDA has granted belzutifan priority review designation based on data from the phase 3 LITESPARK-005 trial. 

FDA Launches Priority Review of Belzutifan for Previously Treated Advanced RCC

Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

Cheryl VerStrate, DNP, AGPCNP-BC, OCN, explains the pitfalls with at-home genomic tests and why nurses must be ready to talk to their patients about genetic counseling. 

Are At-Home Genomic Tests Such as 23andMe Ethical?

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Quality Improvement

1rem

Authors

Jamie Myers Describes the Design of Her Chemotherapy-Related Cognitive Impairment Study

Jamie Myers Describes the Design of Her CRCI Study

Jamie Myers Explains Results From Her Chemotherapy-Related Cognitive Impairment Study

Jamie Myers Explains Results From Her CRCI Study

Jamie Myers, PhD, RN

Articles

Latest Conference Coverage